# Debate prop_0628__claude-fable-5-1-high__gpt-6-astra-high__s0__tpl_placement_active_20260813a

- topic_id: prop_0628
- proposition: Governments should require frontier AI model developers to complete and publish standardized pre-deployment safety evaluations, with penalties for noncompliance.
- model_pro: claude-fable-5-1-high
- model_con: gpt-6-astra-high
- side_swap: False

## Turn 1: PRO Opening

- model: claude-fable-5-1-high
- raw_words: 346
- clipped_words: 340
- claim_ids: [P1.1], [P1.2], [P1.3], [P1.4], [P1.5], [P1.6], [P1.7], [P1.8], [P1.9], [P1.10]
- cited_claim_ids: (none)
- missing_claim_id_refs: (none)

[P1.1] Every frontier lab already tells you it tests its models before release. The question this debate turns on is simpler than it sounds: should a company grading its own homework, with billions riding on the answer, be the only one who ever sees the test?
[P1.2] Today's arrangement fails on three counts. First, evaluations are self-designed, so a lab can quietly choose the benchmarks it passes. Second, results are self-reported, released as glossy "system cards" with whatever redactions marketing prefers. Third, none of it is enforceable.
[P1.3] When one major developer reportedly shipped a model on a compressed timeline and its safety team thinned out afterward, nothing happened, because nothing could happen. A voluntary commitment is a promise that expires the moment a competitor moves faster.
[P1.4] Standardized, mandatory, published evaluations fix each defect. Standardization means the test is set by the regulator, not the examinee, so a strong result actually means something. Publication means hospitals, banks, schools, and the millions of downstream businesses building on these models can compare products on safety rather than on vibes—and it means independent researchers can check the work. Penalties mean the commitment survives a race.
[P1.5] This is not exotic. We do not let aircraft fly on the manufacturer's word that it seemed fine in the hangar. We do not let drugs reach pharmacies because the sponsor felt confident. Every high-consequence industry has learned that pre-market, standardized, disclosed testing is the price of admission—and those industries still innovate.
[P1.6] Aviation got safer and faster simultaneously.
[P1.7] The scope here is deliberately narrow: frontier developers, a handful of well-capitalized firms already running these evaluations internally. The marginal burden is formatting and honesty, not new science. The startup building a customer-service bot is untouched.
[P1.8] Expect the objection that evaluations are imperfect. Of course they are—so was early crash testing. Imperfect public information beats perfect private silence, because public failures get fixed and private ones get buried. Expect the objection that regulators move slowly.
[P1.9] The remedy is a floor that updates, not a shrug.
[P1.10] Frontier models are shaping elections, markets, and biology. [clipped]

## Turn 2: CON Opening

- model: gpt-6-astra-high
- raw_words: 323
- clipped_words: 323
- claim_ids: [C1.1], [C1.2], [C1.3], [C1.4], [C1.5], [C1.6], [C1.7]
- cited_claim_ids: (none)
- missing_claim_id_refs: (none)

[C1.1] The question is not whether frontier developers should face scrutiny. It is whether this particular mandate makes scrutiny meaningful. PRO confuses three things: completing a test, publishing a report, and making deployment safer. The proposition requires the first two, not the third.
[C1.2] Start with what safety evaluations actually measure. A model answering questions in a sandbox is not the same risk as that model operating with private records, internet access, and permission to execute actions. Standardized pre-deployment results can support research, but they cannot establish safety across those settings. PRO promises hospitals and banks comparable safety information when the consequential differences may lie in their integrations.
[C1.3] That is not merely an imperfect measurement; it risks directing attention away from the conditions that produce harm.
[C1.4] Nor is the burden just “formatting and honesty.” Either regulators standardize evaluations developers already conduct, inheriting their blind spots, or they demand genuinely new testing, which requires expertise, infrastructure, and repeated adaptation. A floor can update, but frontier capabilities and deployment configurations can change faster. With penalties attached, firms have a strong incentive to prioritize the legally specified tests over emerging risks that have not reached the checklist.
[C1.5] Publication introduces another tradeoff. Detailed reports can expose exploitable weaknesses or make tests easier to optimize against. Sanitized summaries reduce those dangers, but cannot by themselves deliver the independent verification PRO promises. And nothing in this proposition requires an independent evaluator: a company can still grade its own homework, now using an official worksheet.
[C1.6] The better alternative is enforceable, confidential access for independent evaluators, deployment-specific testing, and continuing incident reporting, with public accountability that protects sensitive findings. Scrutiny should follow actual risk, not stop at a publication deadline.
[C1.7] Crucially, penalties here punish noncompliance with evaluation and publication—not failure to remedy an identified danger. A developer could publish alarming results and satisfy the motion. PRO must justify this particular legal obligation, not borrow the benefits of stronger oversight it does not require.

## Turn 3: PRO Rebuttal 1

- model: claude-fable-5-1-high
- raw_words: 327
- clipped_words: 327
- claim_ids: [P2.1], [P2.2], [P2.3], [P2.4], [P2.5], [P2.6], [P2.7], [P2.8]
- cited_claim_ids: [C1.6], [C1.5], [C1.2], [C1.4], [C1.7]
- missing_claim_id_refs: (none)

[P2.1] Strip away the framing and CON has conceded the motion's spine. Their "better alternative" [C1.6] is *enforceable* access, *mandated* deployment testing, *required* incident reporting, with *public accountability*. That is a mandate, with penalties, with publication. The dispute is now about which tests and how much gets published—and those are questions the regulator answers in implementation, not reasons to vote CON.
[P2.2] Take the independence point [C1.5]. Nothing in "standardized evaluations" says the lab runs them alone. Standardization is precisely what makes third-party verification possible: you cannot audit a test whose design changes with every release. Under the status quo CON is defending by default, independent evaluators get whatever access a lab volunteers, on a lab's timeline.
[P2.3] Standardize first, then independence has something to hold onto.
[P2.4] On sandbox versus deployment [C1.2]: this is a complement, not a rebuttal. Pre-deployment testing is what tells you which integrations are dangerous. A published finding that a model will help a novice through hazardous biology is exactly the information a hospital needs before wiring it to patient records. CON's deployment-specific testing has no baseline without it.
[P2.5] On publication exposing weaknesses [C1.5]: every regulated industry already solves this with tiers—full results to the regulator, redacted summaries publicly, with a defined redaction standard rather than marketing's discretion. Drug trials publish adverse events without publishing synthesis routes. CON is treating a routine design choice as a fatal flaw.
[P2.6] On checklist crowd-out [C1.4]: labs already optimize against benchmarks—privately, invisibly. A public floor at least lets researchers see where the gaming happens and update the floor. Private gaming is unfixable because no one can see it.
[P2.7] Finally, "a developer could publish alarming results and satisfy the motion" [C1.7]. Yes—and that is the mechanism. A company that prints "our model materially uplifts weapons development" on the record faces liability, customers, and every downstream regulator with a document in hand. Today that same finding lives in a Slack channel.
[P2.8] Sunlight does not replace remedy; it is what makes remedy enforceable.

## Turn 4: CON Rebuttal 1

- model: gpt-6-astra-high
- raw_words: 325
- clipped_words: 325
- claim_ids: [C2.1], [C2.2], [C2.3], [C2.4], [C2.5], [C2.6], [C2.7]
- cited_claim_ids: (none)
- missing_claim_id_refs: (none)

[C2.1] Enforceable oversight is not a concession to every reporting mandate. My alternative gives independent evaluators confidential access and follows deployment-specific risks; it does not require standardized public pre-deployment reports. PRO cannot call that distinction “implementation” when standardization and publication are the very obligations we are deciding whether to impose.
[C2.2] Nor does independence require identical tests. An evaluator can examine whether a bespoke test actually probes the relevant danger, demand additional testing, and inspect underlying evidence. Access and expertise make that scrutiny possible—not a common scorecard. PRO’s claim that private gaming is unfixable overlooks precisely the independent, confidential scrutiny I proposed.
[C2.3] A baseline can be useful without being the right legal requirement. PRO’s hospital example exposes the gap: a finding about assistance with hazardous biology does not establish whether a patient-record integration leaks information or takes unauthorized actions. Those require testing the actual system and its permissions. Attaching penalties to a common pre-release checklist gives that checklist institutional priority, even when the consequential questions lie elsewhere.
[C2.4] Publication does not cure that mismatch.
[C2.5] Redaction is sensible, but it does not erase the publication tradeoff. If researchers receive only summaries, they cannot necessarily reproduce the evaluation or identify how it was gamed. If they receive detailed methods and failures, disclosure can aid optimization against the test or exploitation. PRO can narrow publication to reduce that risk—but then much of the promised verification comes from confidential oversight, not public reporting.
[C2.6] Finally, disclosure supplies evidence; it does not itself create a duty to remedy the danger. Customer pressure may help, but customers may also value capability over safety, while outsiders bear the harm. PRO began by rejecting voluntary incentives and now relies on them after the report is filed. A confidential evaluator can also put evidence before a regulator without publishing exploitable findings.
[C2.7] The comparison is not sunlight versus silence. It is risk-directed scrutiny versus making a standardized reporting milestone legally compulsory. PRO has defended scrutiny, not this particular mandate.

## Turn 5: PRO Pressure Questions

- model: claude-fable-5-1-high
- raw_words: 77
- clipped_words: 77
- claim_ids: [P3.1], [P3.2]
- cited_claim_ids: [C2.2], [C2.6]
- missing_claim_id_refs: (none)

[P3.1] Q1: Your evaluators get "confidential access" and can "demand additional testing" [C2.2]—under what legal authority, judged against what published criteria, and with what penalty when a lab refuses, that isn't itself a standardized mandate with penalties for noncompliance?
[P3.2] Q2: You warn customers "may value capability over safety" [C2.6], yet under your confidential regime a hospital choosing between models receives nothing at all. What safety information does a downstream deployer actually get under your alternative, and from whom?

## Turn 6: CON Pressure Questions

- model: gpt-6-astra-high
- raw_words: 56
- clipped_words: 56
- claim_ids: [C3.1], [C3.2]
- cited_claim_ids: (none)
- missing_claim_id_refs: (none)

[C3.1] Q1: What must your redacted public summaries disclose for independent researchers to detect gaming, rather than merely trust the report—and how does that avoid exposing exploitable weaknesses?
[C3.2] Q2: You say publication makes remedy enforceable. What remedy becomes legally available because findings are public that an empowered regulator could not pursue with the same evidence received confidentially?

## Turn 7: PRO Rebuttal 2

- model: claude-fable-5-1-high
- raw_words: 353
- clipped_words: 340
- claim_ids: [P4.1], [P4.2], [P4.3], [P4.4], [P4.5], [P4.6], [P4.7], [P4.8]
- cited_claim_ids: [C2.2], [C2.6]
- missing_claim_id_refs: (none)

[P4.1] A1: The public tier discloses which hazard domains were tested—biology, cyber, autonomy, deception—aggregate results in each, the elicitation conditions (how hard evaluators pushed, whether safeguards were on), who ran the test, and the change from the prior model. It withholds prompts, working jailbreaks, and hazardous outputs; those go in full to the regulator. Detecting gaming doesn't require the prompts. Researchers already have API access to every released frontier model; what they lack is the lab's own claim to test against.
[P4.2] Publish "refuses hazardous synthesis requests roughly 98 percent of the time under adversarial elicitation," and within a week someone knows whether that survives contact with the actual model. Discrepancy is the gaming signal. As for exposure: anyone with an API key finds a model's weaknesses within days regardless. Aggregate publication hands attackers nothing new; it hands defenders a map.
[P4.3] Crash-test stars are public, engineering schematics stay with the regulator. Same design.
[P4.4] A2: For the regulator itself, none—and that is the wrong question. Publication multiplies who can act. A lab that ships despite its own published finding of material weapons uplift has established notice for product-liability suits. Deployers can write compliance thresholds into contracts.
[P4.5] Health regulators, financial supervisors, state attorneys general, and foreign governments can act on the document without rebuilding the evaluation. A false statement in a mandated filing is fraud, not marketing. And a confidential regime hands every remedy to one office that can be underfunded, captured, or slow. Publication is insurance against that office failing.
[P4.6] Now the wider picture. CON's alternative needs legal authority to compel access, criteria for adequate testing, and penalties for refusal [C2.2]. That is a standardized mandate with penalties. My first question asked what else it could be; the answer is still owed, and nothing short of "the motion, renamed" seems available.
[P4.7] My second asked what a hospital receives under confidentiality. The honest answer is nothing—and CON's own warning that customers "may value capability over safety" [C2.6] cuts hardest against a regime guaranteeing they never see the tradeoff.
[P4.8] So the remaining dispute is publication [clipped]

## Turn 8: CON Rebuttal 2

- model: gpt-6-astra-high
- raw_words: 312
- clipped_words: 312
- claim_ids: [C4.1], [C4.2], [C4.3], [C4.4], [C4.5], [C4.6]
- cited_claim_ids: (none)
- missing_claim_id_refs: (none)

[C4.1] A1: Statutory inspection powers would authorize independent evaluators to obtain evidence and require additional, risk-specific testing, with fines for obstructing access or refusing lawful requests. Published criteria would govern evidence adequacy, evaluator independence, and procedural rights—not prescribe a common evaluation battery or require its public release. A common legal duty to cooperate is not a standardized test. PRO conflates enforceable oversight with the particular obligations this motion bundles together.
[C4.2] A2: The hospital receives a deployment-specific assessment from the evaluator: identified risks, relevant limitations, required safeguards, and unresolved uncertainties for its proposed integration. Sensitive exploit details remain restricted; usable warnings do not. Confidential access to underlying evidence does not mean keeping downstream users ignorant, and targeted disclosure is not universal publication of standardized pre-release evaluations.
[C4.3] PRO concedes that publication creates no additional remedy for an empowered regulator. Their remaining case is therefore wider access, not indispensable enforcement. But confidentiality need not concentrate authority in “one office”: independent evaluators and relevant sector regulators can receive the evidence. A published report may help contractual or legal claims, but publication itself neither establishes liability nor guarantees remediation.
[C4.4] Their verification mechanism also overreaches. An aggregate refusal rate cannot be disproved merely by finding failures through an API: results depend on the task distribution and elicitation conditions. Public summaries can flag inconsistencies; they do not automatically expose gaming. And “attackers find weaknesses anyway” is no answer to whether disclosure makes discovery easier.
[C4.5] The decisive comparison is what government makes compulsory. My approach compels access and scrutiny directed at actual uses. PRO compels a standardized reporting milestone, then relies on researchers, customers, and other regulators to translate it into protection. Calling the report a “floor” does not remove its incentive to prioritize checklist compliance over emerging risks.
[C4.6] Prefer enforceable investigation of relevant risks over enforceable completion of a report whose strongest promised benefits still depend on oversight beyond it.

## Turn 9: PRO Closing

- model: claude-fable-5-1-high
- raw_words: 196
- clipped_words: 196
- claim_ids: [P5.1], [P5.2], [P5.3], [P5.4]
- cited_claim_ids: [C4.1], [C4.2], [P4.5], [C2.6]
- missing_claim_id_refs: (none)

[P5.1] Watch what CON's alternative became under pressure. By the final answer [C4.1] it is statutory inspection powers, published criteria, fines for refusal—and, for the hospital [C4.2], a written assessment of risks, limitations, and required safeguards. That is a required evaluation with penalties, delivered as a document. The only thing CON still refuses is that the document be standardized and public.
[P5.2] So the debate resolves to one question: when a frontier model's safety results exist, who is allowed to read them? CON's answer is one evaluator, plus bespoke reports issued deployer by deployer, none comparable against anyone else's. Mine is: the regulator gets everything, and everyone else gets the aggregate scorecard.
[P5.3] Weigh those. CON never disputed that a confidential regime can be underfunded, captured, or slow [P4.5]; the reply was that "sector regulators" can also see the evidence—more offices, still no public. A regime whose findings no outsider can check is the status quo with a badge. And CON's own worry that customers "may value capability over safety" [C2.6] argues for showing them the tradeoff, not hiding it.
[P5.4] Standardization is what lets the hospital compare. Publication is what lets anyone catch the evaluator being wrong. Vote PRO.

## Turn 10: CON Closing

- model: gpt-6-astra-high
- raw_words: 198
- clipped_words: 198
- claim_ids: [C5.1], [C5.2], [C5.3], [C5.4], [C5.5], [C5.6]
- cited_claim_ids: (none)
- missing_claim_id_refs: (none)

[C5.1] The decisive distinction is not secrecy versus sunlight. It is whether the information published supports the safety judgment PRO asks the public to make.
[C5.2] A standardized model score does not establish whether a hospital’s actual integration leaks records or takes unauthorized actions. Those risks depend on permissions, tools, and deployment conditions. A common scorecard makes results easier to rank; it does not establish that the ranking answers the consequential question.
[C5.3] That matters because penalties give the prescribed reporting milestone institutional priority over risks outside its frame.
[C5.4] PRO’s final promise—“publication is what lets anyone catch the evaluator being wrong”—also exceeds their design. Aggregate results without the underlying test distribution cannot reliably be audited by finding failures through an API. Publication may prompt questions, but the access and investigation needed to answer them remain the substance of oversight.
[C5.5] That is why enforceable independent access, risk-specific testing, and usable warnings to deployers are not “the status quo with a badge.” They compel scrutiny without pretending universal publication supplies verification.
[C5.6] Useful reports can complement safety oversight. PRO has not justified making this particular report compulsory. Prefer a legal obligation directed at investigating consequential risks over one directed at producing a comparable scorecard.
